Antibody Immunogen Source: Human ERK2 (MAPK1) sequence peptide Cat. No.: PE-04AGD95
Antibody Immunogen Sequence: GFL(pT)E(pY)V(bA)C
Antibody Immunogen Description: Corresponds to amino acid residues G182 to V188; In the protein kinase catalytic domain activation T loop region between subdomains VII and VIII.
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.This antibody was also subject to negative purification over phosphotyrosine-agarose.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 1 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Potency: Strong immunoreactivity of a target-sized protein by Western blotting in maturing sea star oocyte and A431 cells. It also detects in ERK1 and ERK2 in A549, HeLa, and MCF7 cells. Medium immunoreactivity with immunogen peptide on dot blots. Very strong immunoreactivity with recombinant human ERK2 on protein dot blots.
Scientific Background: ERK2 (MAPK1) is a protein-serine/threonine kinase of the CMGC group and MAPK family. It is involved in the MAP Kinase signalling pathway. The MAP kinase pathway can mediate cell adhesion, growth, survival, differentiation, meiosis, mitosis, and other post-mitotic functions. Phosphorylation of T185 and Y187 by MEK1 an MEK2 increases its phosphotransferase activity. It phosphorylates many diffrent transcription factors, such as ELK1. It acts as transcriptional repressor by binding directly to DNA. It is essential for cyclin D1 induction. MAPK1 phosphorylates BCL2, which contributes to cell survival, the suppression of the apoptotic effect of BAD and up-regulation of the antiapoptotic protein MCL-1. It regulates accumulation of p53 during DNA damage response. ERK2 appears to be a tumour requiring protein (TRP). The active form of the protein kinase normally acts to promote tumour cell proliferation. ERK2 has been linked with the Ewing's Family of tumours, which are rare cancers that are similar to medullablastoma and cerebral primitive neuroectodermal tumours. It is constitutively active in many human tumours, primarily due to altered Ras, Raf, EGFR or other upstream oncoproteins.